News

Filter

Current filters:

dabrafenibZelboraf

MEK inhibitors: new weapon in the fight against melanoma

24-06-2012

Cancer cell signaling has long been an attractive target for oncology drug development. Increased activation…

dabrafenibGlaxoSmithKlineOncologyPharmaceuticalResearchRochetrametinibZelboraf

Malignant melanoma drug market to grow more than seven-fold to $1.5 billion in 2020

05-10-2011

The market for malignant melanoma drugs is forecast to expand more than seven-fold over the next decade,…

dabrafenibGlobalMarkets & MarketingOncologyPharmaceuticaltrametinibYervoyZelboraf

Back to top